Welcome to our dedicated page for Catheter Precision SEC filings (Ticker: VTAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the FDA trial outcomes buried in Catheter Precision’s 10-K can feel like navigating a cardiac maze. The disclosures span VIVO non-invasive mapping performance, LockeT vascular-closure margins, and CE-mark timelines—details investors need but rarely have time to parse. It’s why so many search “Catheter Precision SEC filings explained simply” or ask for a “Catheter Precision annual report 10-K simplified.”
Stock Titan decodes the complexity the instant an update hits EDGAR. Whether you’re looking for a “Catheter Precision quarterly earnings report 10-Q filing” or want “Catheter Precision 8-K material events explained,” our AI delivers crisp summaries, red-flag callouts, and trend charts. Real-time alerts push “Catheter Precision Form 4 insider transactions real-time” straight to your dashboard, so you know the moment executives trade shares. For professionals, understanding Catheter Precision SEC documents with AI is now as direct as a chart review.
Use the filings the way seasoned analysts do:
- Product economics: 10-Q segments reveal average selling prices for VIVO; our AI spots sequential changes.
- Regulatory momentum: Each 8-K logs new clinical milestones, instantly summarized for quick context.
- Capital needs: Shelf registrations hint at funding rounds for additional catheter studies.
If governance is your focus, one click surfaces the “Catheter Precision proxy statement executive compensation” tables alongside peer benchmarks. Need “Catheter Precision insider trading Form 4 transactions” or “Catheter Precision executive stock transactions Form 4”? Our AI clusters every buy and sell by date, value, and intent. The result: concise “Catheter Precision earnings report filing analysis” in seconds—not evenings—turning dense disclosures into confident, timely decisions.
Catheter Precision, Inc. director James J. Caruso reported a small equity transaction in the company’s stock. On 12/05/2025, he acquired 41 shares of common stock at a price of $0 per share in a transaction coded “C,” indicating a conversion. Following this transaction, he directly beneficially owned 50 shares of common stock.
The filing also shows activity in Series X Convertible Preferred Stock, with a conversion price of $0. On the same date, 7.932 shares of this preferred stock were involved in a transaction coded “C,” with no common shares shown as underlying afterward and 0 derivative securities beneficially owned. The accompanying note explains that the Series X Convertible Preferred Stock has no expiration date.
Catheter Precision, Inc. reported an insider stock transaction by its Chairman and CEO, David A. Jenkins. On 12/05/2025, Jenkins converted shares of Series X Convertible Preferred Stock into common stock at a stated price of $0 per share. Following these conversions, he directly held 13,799 common shares, with an additional 34,579 shares held indirectly through a partnership and 109 shares held indirectly through a charitable remainder unitrust. The filing notes that the preferred stock has no expiration date and that some of the indirectly held shares are controlled via entities managed by Jenkins or his spouse, clarifying the structure of his beneficial ownership.
Catheter Precision, Inc. reported that it has given notice to terminate its At-Market-Offering Agreement with Ladenburg Thalmann & Co. Inc., which supported its at-the-market equity offering program. The termination is scheduled to be effective on November 24, 2025.
The program allowed the company to offer and sell shares of common stock with an aggregate offering price of up to $4.3 million. Before issuing the termination notice, Catheter Precision sold approximately $4.0 million of common stock under this program, and it will not owe any termination penalties.
Catheter Precision, Inc. (VTAK) reported that it furnished a press release announcing financial results for the three and nine months ended September 30, 2025. The company provided this update under Item 2.02 of the Exchange Act.
The press release is included as Exhibit 99.1 and, as stated, the information is being furnished and not deemed filed under Section 18. VTAK’s common stock trades on NYSE American.
Catheter Precision, Inc. reported Q3 2025 results showing small but growing sales and ongoing losses, alongside a going concern warning. Revenue was
Cash and cash equivalents were
To fund operations, the company completed a private placement on
Catheter Precision (VTAK) reported the results of a stockholder Special Meeting held on October 10, 2025. Of the 1,487,266 shares outstanding as of September 10, 2025 (the record date), 641,616 shares were represented in person or by proxy, constituting approximately 43.1% of shares entitled to vote.
Stockholders considered three proposals. Reported vote totals were: Proposal 1 — 497,162 for, 133,882 against, 10,571 abstentions; Proposal 2 — 610,134 for, 16,778 against, 14,703 abstentions; Proposal 3 — 514,362 for, 120,394 against, 6,860 abstentions.
Catheter Precision filed an 8-K to attach a legal opinion supporting its Form S-3 prospectus supplement and to announce that its LockeT surgical vessel closing device received regulatory approval in Great Britain. The press release highlights potential benefits of LockeT for patient comfort, faster recovery and increased clinical throughput, but also contains extensive forward-looking cautionary language. The company discloses material weaknesses in internal control, a history of losses, the need to raise additional funds to continue operations, and multiple operational and market risks including competition, reimbursement, supply-chain and regulatory challenges.
Catheter Precision, Inc. implemented a 1-for-19 reverse stock split of its common stock after stockholder authorization, effective at 12:01 a.m. ET on August 15, 2025. The company combined every 19 issued shares into one share and reduced issued and outstanding common shares from approximately 23,327,516 to approximately 1,227,764. The common stock continues to trade under the symbol VTAK on the NYSE American on a split-adjusted basis and received a new CUSIP number.
Authorized capital remains unchanged at 10 million preferred and 60 million common shares. Proportionate adjustments were made to outstanding stock options, warrants, conversion prices and shares available under incentive plans. Fractional shares will not be issued; holders entitled to fractions will receive cash pro rata from aggregated fractional-share sales, net of customary fees.
FAQ
What is the current stock price of Catheter Precision (VTAK)?
What is the market cap of Catheter Precision (VTAK)?
